Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
APT Medical Inc. (688617.SS)
Shenzhen, CN
APT Medical Inc. is a global enterprise dedicated to the research, development, production, and commercialization of invasive interventional medical devices primarily targeting cardiovascular and cerebrovascular diseases. Its extensive product portfolio encompasses a range of electrophysiological tools, including catheter delivery systems, alongside radiofrequency ablation and mapping catheters. Additionally, APT Medical provides various vascular intervention solutions, spanning diagnostic and therapeutic devices, as well as essential intervention accessories. Beyond its proprietary offerings, the company extends its expertise through OEM (Original Equipment Manufacturer) and ODM (Original Design Manufacturer) services for catheter and metal-based products, including associated accessories. Established in 2002, APT Medical maintains its corporate headquarters in Shenzhen, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.37% | -4.47% | -13.57% | -16.51% | -12.18% | -15.49% | -24.82% | +14.74% | +25.50% | +15.98% | +15.98% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+25.1% ★ Q1'26: +24.8% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+22.0% Q1'26: +25.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+33.4% ★ Q1'26: +18.3% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+36.2% ★ Q1'26: +36.3% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+50.2% ★ Q1'26: +50.2% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%0.0% ★ Q1'26: -0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.02× ★ Q1'26: 0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 4 EPS Ana. |
Dec 2027 9 Rev. Ana. 8 EPS Ana. |
Dec 2028 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
479.44M
est: 483.00M (-0.7%)
|
828.69M
est: 833.22M (-0.5%)
|
1.22B
est: 1.24B (-2.2%)
|
1.65B
est: 1.86B (-11.4%)
|
2.07B
est: 2.13B (-2.9%)
|
2.58B
est: 2.59B (-0.1%)
|
3.25B
3.21B – 3.29B
+25.8% YoY
|
4.05B
3.86B – 4.52B
+24.7% YoY
|
5.04B
5.03B – 5.05B
+24.3% YoY
|
| EBITDA |
142.19M
est: 152.39M (-6.7%)
|
251.16M
est: 262.89M (-4.5%)
|
437.51M
est: 392.18M (+11.6%)
|
656.42M
est: 905.98M (-27.5%)
|
824.98M
est: 1.03B (-20.2%)
|
1.01B
est: 1.26B (-19.4%)
|
1.58B
1.56B – 1.60B
+25.8% YoY
|
1.97B
1.88B – 2.20B
+24.7% YoY
|
2.45B
2.45B – 2.45B
+24.3% YoY
|
| EBIT |
122.19M
est: 135.02M (-9.5%)
|
223.35M
est: 232.92M (-4.1%)
|
396.81M
est: 347.48M (+14.2%)
|
600.38M
est: 854.14M (-29.7%)
|
748.32M
est: 975.04M (-23.3%)
|
936.29M
est: 1.19B (-21.0%)
|
1.49B
1.47B – 1.51B
+25.8% YoY
|
1.86B
1.77B – 2.07B
+24.7% YoY
|
2.31B
2.31B – 2.31B
+24.3% YoY
|
| Net Income |
110.78M
est: 75.88M (+46.0%)
|
207.92M
est: 144.97M (+43.4%)
|
358.02M
est: 237.74M (+50.6%)
|
533.92M
est: 927.40M (-42.4%)
|
673.15M
est: 755.75M (-10.9%)
|
820.64M
est: 866.92M (-5.3%)
|
1.02B
1.01B – 1.05B
+18.0% YoY
|
1.32B
1.21B – 1.45B
+28.8% YoY
|
1.64B
1.56B – 1.73B
+24.8% YoY
|
| SGA |
152.50M
est: 128.99M (+18.2%)
|
251.43M
est: 222.52M (+13.0%)
|
307.57M
est: 331.95M (-7.3%)
|
386.96M
est: 378.45M (+2.2%)
|
464.34M
est: 432.02M (+7.5%)
|
—
est: 525.29M (-100.0%)
|
660.59M
651.11M – 668.86M
+25.8% YoY
|
823.43M
785.05M – 918.99M
+24.7% YoY
|
1.02B
1.02B – 1.03B
+24.3% YoY
|
| EPS |
1.06
est: 0.78 (+35.9%)
|
1.52
est: 1.49 (+2.0%)
|
2.56
est: 2.44 (+4.7%)
|
3.82
est: 6.42 (-40.5%)
|
4.80
est: 5.28 (-9.2%)
|
5.82
est: 5.92 (-1.6%)
|
7.29
7.17 – 7.42
+23.2% YoY
|
9.14
8.56 – 10.27
+25.3% YoY
|
11.51
11.03 – 12.24
+26.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | KraneShares MSCI All China Health Care Index ETF KURE | 0.73% | 580.9K | 0.79% |
| 2 | KraneShares ICBCUBS SSE Star Market 50 Index UCITS ETF KSTR.L | 0.54% | 363.7K | 0.82% |
| 3 | KraneShares SSE STAR Market 50 Index ETF KSTR | 0.53% | 2.06M | 0.89% |
| 4 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.16% | 58.4K | 0.65% |
| 5 | HSBC MSCI China A UCITS ETF HMCT.L | 0.10% | 134.4K | 0.30% |
| 6 | iShares MSCI China A UCITS ETF CNYA.L | 0.06% | 1.77M | 0.40% |
| 7 | iShares MSCI China A UCITS ETF CNYE.MI | 0.06% | 58.5K | 0.45% |
| 8 | iShares MSCI China A ETF CNYA | 0.06% | 133.0K | 0.60% |
| 9 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.05% | 8.9K | 0.65% |
| 10 | Xtrackers MSCI China A UCITS ETF 1C XX2D.L | 0.05% | 73.3K | 0.35% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fangyuan Liu | Deputy General Manager | — | male |
| Qi Han Gui | Financial Officer | — | female |
| Wang Jinhe | Deputy General Manager | — | male |
| Wei Wang | Deputy General Manager | — | male |
| Yiqing Xu | Deputy General Manager | — | male |
| Yonggui Han | Deputy General Manager | — | male |
| Yuchen Qiu | Deputy General Manager | — | male |
| Zhenghui Cheng | President, GM & Vice Chairman | — | male |
| Zhenhua Dai | Deputy GM & Employee Representative Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688617.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
